You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClonidine
Accession NumberDB00575  (APRD00174, DB07566)
TypeSmall Molecule
GroupsApproved
DescriptionClonidine, an imidazoline-derivative hypotensive agent is a centrally-acting α2-adrenergic agonist. It crosses the blood-brain barrier and acts in the hypothalamus to induce a decrease in blood pressure. It may also be administered as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone. Clonidine may be used for differential diagnosis of pheochromocytoma in hypertensive patients. Other uses for clonidine include prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD). Clonidine also exhibits some peripheral activity.
Structure
Thumb
Synonyms
2-[(2,6-Dichlorophenyl)imino]imidazoline
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
Chlofazoline
Clonidin
Clonidina
Clonidinum
External Identifiers
  • ST 155
  • ST 155-BS
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CatapresPatch, extended release.1 mg/24hTransdermalBoehringer Ingelheim Pharmaceuticals Inc.1985-10-01Not applicableUs
CatapresPatch, extended release.2 mg/24hTransdermalBoehringer Ingelheim Pharmaceuticals Inc.1985-10-01Not applicableUs
CatapresTablet.1 mg/1OralBoehringer Ingelheim Pharmaceuticals Inc.1999-05-01Not applicableUs
CatapresTablet.1 mg/1OralREMEDYREPACK INC.2016-10-07Not applicableUs
CatapresPatch, extended release.3 mg/24hTransdermalBoehringer Ingelheim Pharmaceuticals Inc.1985-10-01Not applicableUs
CatapresTablet.2 mg/1OralBoehringer Ingelheim Pharmaceuticals Inc.1999-05-01Not applicableUs
CatapresPatch, extended release.1 mg/24hTransdermalRebel Distributors Corp1985-10-01Not applicableUs
CatapresTablet.3 mg/1OralBoehringer Ingelheim Pharmaceuticals Inc.1999-05-01Not applicableUs
Catapres Tab 0.1mgTablet0.1 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1973-12-31Not applicableCanada
Catapres Tab 0.2mgTablet0.2 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1974-12-312015-03-30Canada
ClonidineTablet0.1 mgOralSanis Health Inc2011-02-082012-08-03Canada
ClonidineTablet0.2 mgOralSanis Health Inc2011-02-082012-08-03Canada
ClonidineTablet0.025 mgOralSanis Health Inc2011-02-082012-08-03Canada
Clonidine 0.1Tablet0.1 mgOralPro Doc Limitee1991-12-312014-07-24Canada
Clonidine HCl Tab 0.2mgTablet.2 mgOralPro Doc Limitee1991-12-312014-07-24Canada
Clonidine HydrochlorideTablet.3 mg/1OralState of Florida DOH Central Pharmacy2009-06-20Not applicableUs
Clonidine Hydrochloride Extended-releaseTablet, extended release.1 mg/1OralConcordia Pharmaceuticals Inc.2010-12-092017-03-31Us
Clonidine Hydrochloride Extended-releaseTablet, extended release.1 mg/1OralPrasco Laboratories2016-06-20Not applicableUs
Dixarit Tab 0.025mgTablet0.025 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1981-12-312016-10-22Canada
Dom-clonidineTablet.1 mgOralDominion Pharmacal2003-05-22Not applicableCanada
Dom-clonidineTablet.2 mgOralDominion Pharmacal2003-05-22Not applicableCanada
DuraclonInjection, solution.1 mg/mLEpiduralMylan Institutional LLC1996-10-02Not applicableUs
DuraclonInjection, solution.5 mg/mLEpiduralMylan Institutional LLC1996-10-02Not applicableUs
KapvayTablet, extended release.1 mg/1OralConcordia Pharmaceuticals Inc.2010-12-09Not applicableUs
KapvayTablet, extended release.2 mg/1OralConcordia Pharmaceuticals Inc.2010-12-09Not applicableUs
NexiclonTablet, extended release.17 mg/1OralTris Pharma, Inc.2010-12-172016-11-22Us
Nexiclon XRFor suspension, extended release.09 mg/mLOralTris Pharma, Inc.2010-12-172016-11-22Us
Nexiclon XRTablet, extended release.26 mg/1OralTris Pharma, Inc.2010-12-172016-11-22Us
Ntp-clonidineTablet0.2 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-clonidineTablet0.025 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-clonidineTablet0.1 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-clonidine Tab 0.1mgTablet.1 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Nu-clonidine Tab 0.2mgTablet.2 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Teva-clonidineTablet0.025 mgOralTeva Canada Limited2008-06-26Not applicableCanada
Teva-clonidineTablet0.1 mgOralTeva Canada Limited1993-12-31Not applicableCanada
Teva-clonidineTablet0.2 mgOralTeva Canada Limited1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clonidineTablet0.025 mgOralApotex Inc2004-07-13Not applicableCanada
Apo-clonidine Tab 0.1mgTablet.1 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-clonidine Tab 0.2mgTablet.2 mgOralApotex Inc1990-12-31Not applicableCanada
ClonidinePatch, extended release.1 mg/24hTransdermalMayne Pharma Inc.2016-08-03Not applicableUs
ClonidinePatch.2 mg/dTransdermalLake Erie Medical DBA Quality Care Products LLC2013-02-08Not applicableUs
ClonidineInjection, solution100 ug/mLEpiduralX Gen Pharmaceuticals, Inc.2013-10-29Not applicableUs
ClonidinePatch.2 mg/dTransdermalMylan Pharmaceuticals Inc.2013-02-08Not applicableUs
ClonidinePatch.3 mg/dTransdermalPhysicians Total Care, Inc.2011-05-10Not applicableUs
ClonidinePatch, extended release.2 mg/24hTransdermalMayne Pharma Inc.2016-08-03Not applicableUs
ClonidinePatch, extended release.1 mg/24hTransdermalTeva Pharmaceuticals Usa, Inc.2010-08-25Not applicableUs
ClonidineInjection, solution500 ug/mLEpiduralX Gen Pharmaceuticals, Inc.2013-10-29Not applicableUs
ClonidinePatch.3 mg/dTransdermalMylan Pharmaceuticals Inc.2013-02-08Not applicableUs
ClonidinePatch, extended release.2 mg/24hTransdermalLake Erie Medical DBA Quality Care Products LLC2010-08-25Not applicableUs
ClonidinePatch.1 mg/dTransdermalPhysicians Total Care, Inc.2011-09-24Not applicableUs
ClonidinePatch, extended release.3 mg/24hTransdermalMayne Pharma Inc.2016-08-03Not applicableUs
ClonidinePatch, extended release.2 mg/24hTransdermalTeva Pharmaceuticals Usa, Inc.2010-08-25Not applicableUs
ClonidinePatch.1 mg/dTransdermalMylan Pharmaceuticals Inc.2013-02-08Not applicableUs
ClonidinePatch.2 mg/dTransdermalPhysicians Total Care, Inc.2010-12-14Not applicableUs
ClonidinePatch, extended release.3 mg/24hTransdermalTeva Pharmaceuticals Usa, Inc.2010-08-25Not applicableUs
ClonidineTablet.1 mg/1OralSTAT Rx USA LLC1986-12-16Not applicableUs
ClonidineInjection, solution500 ug/mLEpiduralFresenius Kabi USA, LLC2011-07-08Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralDIRECT RX2015-12-29Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralMed Vantx, Inc.2011-12-13Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralPd Rx Pharmaceuticals, Inc.1987-06-09Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralMylan Pharmaceuticals Inc.1987-06-09Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralA S Medication Solutions2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2011-04-04Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralREMEDYREPACK INC.2011-07-292016-11-02Us
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2012-08-202016-10-18Us
Clonidine HydrochlorideTablet.1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralCardinal Health2006-11-20Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralAmerican Health Packaging2015-10-01Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralCarlsbad Technology, Inc2013-06-17Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1Oralbryant ranch prepack1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPreferred Pharmaceuticals, Inc.2011-11-10Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralActavis Pharma, Inc.1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-12-012016-11-29Us
Clonidine HydrochlorideTablet.2 mg/1OralPreferred Pharmaceuticals, Inc.2011-11-10Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralNu Care Pharmaceuticals, Inc.2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralSTAT Rx USA LLC2009-09-03Not applicableUs
Clonidine HydrochlorideInjection, solution500 ug/mLEpiduralAmerican Regent, Inc.2010-04-15Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralUnit Dose Services2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralMutual Pharmaceutical Company, Inc.1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPhysicians Total Care, Inc.2001-10-03Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralREMEDYREPACK INC.2014-07-18Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralA S Medication Solutions Llc2013-02-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralCardinal Health2009-09-03Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralProficient Rx LP1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralBlue Point Laboratories2014-03-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPd Rx Pharmaceuticals, Inc.2009-09-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2015-09-10Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralLake Erie Medical DBA Quality Care Products LLC1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralQualitest Pharmaceuticals2007-03-092018-09-23Us
Clonidine HydrochlorideTablet.1 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralMed Health Pharma, LLC2011-01-10Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralClinical Solutions Wholesale2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2015-07-17Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralTYA Pharmaceuticals1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralMc Kesson Contract Packaging2011-10-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Clonidine HydrochlorideInjection, solution100 ug/mLIntravenousWest ward Pharmaceutical Corp2011-01-01Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPd Rx Pharmaceuticals, Inc.2013-06-17Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralUnit Dose Services2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralRebel Distributors Corp1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralMajor Pharmaceuticals2006-11-20Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralMylan Institutional Inc.1995-06-12Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPd Rx Pharmaceuticals, Inc.2009-09-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralCardinal Health2011-07-08Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralAmerican Health Packaging2015-10-01Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralAmerican Health Packaging2013-05-20Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralDispensing Solutions, Inc.2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralAvera Mc Kennan Hospital2015-03-05Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2015-03-20Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralMylan Pharmaceuticals Inc.1987-06-09Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralA S Medication Solutions2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2013-02-26Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2011-08-012016-11-03Us
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2013-03-18Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralPhysicians Total Care, Inc.1995-01-09Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralClinical Solutions Wholesale, Llc2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralREMEDYREPACK INC.2014-11-03Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1Oralbryant ranch prepack1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-13Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-12-012016-11-29Us
Clonidine HydrochlorideTablet.1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralNu Care Pharmaceuticals, Inc.2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralNorth Star Rx Llc2013-02-042016-10-13Us
Clonidine HydrochlorideTablet.1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-12-16Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralAidarex Pharmaceuticals LLC2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralUnit Dose Services1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralA S Medication Solutions Llc2013-06-17Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralRichmond Pharmaceuticals, Inc.1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralCardinal Health2009-09-03Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralProficient Rx LP2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralBlue Point Laboratories2014-03-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2016-04-11Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralREMEDYREPACK INC.2015-11-25Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralAlembic Pharmaceuticals Inc.2016-05-03Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralQualitest Pharmaceuticals2007-03-092017-07-31Us
Clonidine HydrochlorideTablet.2 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralUnit Dose Services2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralRebel Distributors Corp1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralMajor Pharmaceuticals2006-11-20Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPd Rx Pharmaceuticals, Inc.1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-25Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralClinical Solutions Wholesale2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralREMEDYREPACK INC.2015-11-12Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralTYA Pharmaceuticals2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Clonidine HydrochlorideTablet, extended release.1 mg/1OralActavis Pharma, Inc.2015-06-17Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralPd Rx Pharmaceuticals, Inc.2013-06-17Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2013-06-09Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralCardinal Health2011-07-08Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralAmerican Health Packaging2015-10-01Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralAmerican Health Packaging2013-05-20Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralContract Pharmacy Services Pa2010-08-18Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralREMEDYREPACK INC.2015-07-30Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralMylan Pharmaceuticals Inc.1987-06-09Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralA S Medication Solutions1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralAidarex Pharmaceuticals LLC1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralBlenheim Pharmacal, Inc.2011-04-01Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralREMEDYREPACK INC.2011-08-052016-11-03Us
Clonidine HydrochlorideTablet.1 mg/1OralMed Health Pharma, LLC2011-01-10Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralPhysicians Total Care, Inc.2004-11-30Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralClinical Solutions Wholesale, Llc2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralREMEDYREPACK INC.2015-06-16Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1Oralbryant ranch prepack2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPreferred Pharmaceuticals, Inc.2014-10-22Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-12-012016-11-29Us
Clonidine HydrochlorideTablet.2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralPreferred Pharmaceuticals Inc.2016-08-31Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralNorth Star Rx Llc2013-02-042016-10-13Us
Clonidine HydrochlorideTablet.2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-12-16Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralMylan Institutional Inc.1997-02-14Not applicableUs
Clonidine HydrochlorideInjection, solution100 ug/mLEpiduralPharma Force, Inc.2009-10-16Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralAlembic Pharmaceuticals Inc.2016-05-03Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralQualitest Pharmaceuticals2007-03-092017-07-31Us
Clonidine HydrochlorideTablet.2 mg/1OralLake Erie Medical DBA Quality Care Products LLC1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralApotheca, Inc1996-12-21Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralMutual Pharmaceutical Company, Inc.1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralRichmond Pharmaceuticals, Inc.1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralCardinal Health2013-06-17Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralCarlsbad Technology, Inc2013-06-17Not applicableUs
Clonidine HydrochlorideInjection, solution100 ug/mLEpiduralFresenius Kabi USA, LLC2011-07-08Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralBlue Point Laboratories2014-03-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralActavis Pharma, Inc.1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralDIRECT RX2015-01-01Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Clonidine HydrochlorideTablet, extended release.2 mg/1OralActavis Pharma, Inc.2015-06-17Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralA S Medication Solutions1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralA S Medication Solutions2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralRebel Distributors Corp1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralMajor Pharmaceuticals2006-11-20Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralREMEDYREPACK INC.2011-03-282016-10-18Us
Clonidine HydrochlorideTablet.2 mg/1OralNorthwind Pharmaceuticals, LLC2014-09-24Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralDispensing Solutions, Inc.2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralDIRECT RX2015-01-01Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralMed Vantx, Inc.1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2013-08-28Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralCardinal Health2011-07-08Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralSt Marys Medical Park Pharmacy2010-03-01Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralAmerican Health Packaging2013-05-20Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralContract Pharmacy Services Pa2010-07-29Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralUnit Dose Services1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralREMEDYREPACK INC.2015-08-31Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralLake Erie Medical DBA Quality Care Products LLC1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralDIRECT RX2014-01-01Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralAidarex Pharmaceuticals LLC2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralBlenheim Pharmacal, Inc.2010-04-08Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-05-19Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralMed Health Pharma, LLC2011-01-10Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralClinical Solutions Wholesale2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralREMEDYREPACK INC.2015-03-07Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralMc Kesson Contract Packaging2012-01-10Not applicableUs
Clonidine HydrochlorideInjection, solution500 ug/mLIntravenousWest ward Pharmaceutical Corp2011-01-01Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralPd Rx Pharmaceuticals, Inc.2013-06-17Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralUnit Dose Services2009-09-21Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralNorth Star Rx Llc2013-02-042016-10-13Us
Clonidine HydrochlorideTablet.3 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-12-16Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralMylan Institutional Inc.1995-06-12Not applicableUs
Clonidine HydrochlorideInjection, solution500 ug/mLEpiduralPharma Force, Inc.2009-10-16Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralActavis Pharma, Inc.1995-01-03Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralPreferred Pharmaceuticals, Inc.2011-11-10Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralAlembic Pharmaceuticals Inc.2016-05-03Not applicableUs
Clonidine HydrochlorideInjection, solution100 ug/mLEpiduralAmerican Regent, Inc.2010-04-15Not applicableUs
Clonidine HydrochlorideTablet.1 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralA S Medication Solutions Llc2007-03-09Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralMutual Pharmaceutical Company, Inc.1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralRichmond Pharmaceuticals, Inc.1987-09-04Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralPd Rx Pharmaceuticals, Inc.2009-09-03Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralCarlsbad Technology, Inc2013-06-17Not applicableUs
Clonidine Hydrochloride Extended-releaseTablet, extended release.1 mg/1OralPar Pharmaceutical2013-09-30Not applicableUs
Clonidine Hydrochloride Extended-releaseTablet, extended release.2 mg/1OralPar Pharmaceutical2013-09-30Not applicableUs
Clonidine Hydrochloride Extended-releaseTablet, extended release.1 mg/1OralGolden State Medical Supply, Inc.2015-09-30Not applicableUs
Clonidine Hydrochloride Extended-releaseTablet, extended release.1 mg/1OralAmerican Health Packaging2014-10-27Not applicableUs
Clonidine Transdermal SystemPatch.3 mg/dTransdermalActavis Pharma, Inc.2014-05-06Not applicableUs
Clonidine Transdermal SystemPatch.1 mg/dTransdermalActavis Pharma, Inc.2014-05-06Not applicableUs
Clonidine Transdermal SystemPatch.2 mg/dTransdermalActavis Pharma, Inc.2014-05-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Catapres-TTSBoehringer Ingelheim
CatapresanBoehringer Ingelheim
CatapressanBoehringer Ingelheim
DixaritBoehringer Ingelheim
IsoglauconAgepha
Run RuiBausch & Lomb
VelarilRoemmers
WinpressWinston
Brand mixtures
NameLabellerIngredients
ClorpresMylan Pharmaceuticals Inc.
Combipres 0.1/15 TabBoehringer Ingelheim (Canada) Ltd Ltee
Salts
Name/CASStructureProperties
Clonidine Hydrochloride
4205-91-8
Thumb
  • InChI Key: ZNIFSRGNXRYGHF-UHFFFAOYSA-N
  • Monoisotopic Mass: 264.994030456
  • Average Mass: 266.555
DBSALT000538
Categories
UNIIMN3L5RMN02
CAS number4205-90-7
WeightAverage: 230.094
Monoisotopic: 229.017352717
Chemical FormulaC9H9Cl2N3
InChI KeyGJSURZIOUXUGAL-UHFFFAOYSA-N
InChI
InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
IUPAC Name
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
SMILES
ClC1=CC=CC(Cl)=C1NC1=NCCN1
Pharmacology
IndicationMay be used as an adjunct in the treatment of hypertension, as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone, for differential diagnosis of pheochromocytoma in hypertensive patients, prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD).
Structured Indications
PharmacodynamicsClonidine is an α-adrenergic agent that acts specifically on α2-receptors. α2-receptors regulate a number of signaling pathways mediated by multiple Gi proteins, Gαi1, Gαi2, and G&alphai3. Stimulation of α2-receptors mediates effects such as inhibition of adenylyl cyclase, stimulation fo phospholipase D, stimulation of mitogen-activated protein kinases, stimulation of K+ currents and inhibition of Ca2+ currents. Three G-protein coupled α2-receptor subtypes have been identified: α2A, α2B, and α2C. Each subtype has a unique pattern of tissue distribution in the central nervous system and peripheral tissues. The α2A-receptor is widely distributed throughout the central nervous system; it is found in the locus coeruleus, brain stem nuclei, cerebral cortex, septum, hypothalamus, and hippocampus. α2A-receptors are also expressed in the kidneys, spleen, thymus, lung and salivary glands. The α2C-receptor is primarily expressed in the central nervous system, including the striatum, olfactory tubercle, hippocampus and cerebral cortex. Low levels of the α2C-subtype are also found in the kidneys. The α2B-receptor is located primarily in the periphery (kidney, liver, lung and heart) with low levels of expression in the thalamic nuclei of the central nervous system. The α2A- and α2C-receptors are located presynaptically and inhibit the released of noradrenaline from sympathetic nerves. Stimulation of these receptors decreases sympathetic tone, resulting in decreases in blood pressure and heart rate. Sedation and analgesia is mediated by centrally located α2A-receptors, while peripheral α2B-receptors mediate constriction of vascular smooth muscle. α2A-Receptors also mediate essential components of the analgesic effect of nitrous oxide in the spinal cord. Clonidine stimulates all three α2-receptor subtypes with similar potency. Its actions in the nervous system decreases blood pressure in patients with hypertension and decreases sympathetic overactivity in patients undergoing opioid withdrawal. Clonidine is also a potent sedative and analgesic and can prevent post-operative shivering in intensive and post-operative care. Its use in differential diagnosis of pheochromocytoma owes to the fact that hypertension in patients with pheochromocytoma is refractory to antihypertensive treatment with clonidine.
Mechanism of actionSee Pharmacology section above.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-2A adrenergic receptorProteinyes
agonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinyes
agonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinyes
agonist
HumanP18825 details
Alpha-1A adrenergic receptorProteinunknown
agonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
agonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinunknown
agonist
HumanP25100 details
Related Articles
AbsorptionWell absorbed following oral administration. Bioavailability following chronic administration is approximately 65%.
Volume of distributionNot Available
Protein binding20-40%, primarily to albumin
Metabolism

Hepatic. Metabolized via minor pathways. The major metabolite, p-hydroxyclonidine, is present in concentrations less than 10% of those of unchanged clonidine in urine. Four metabolites have been detected, but only p-hydroxyclonidine has been identified.

SubstrateEnzymesProduct
Clonidine
4-HydroxyclonidineDetails
Route of eliminationNot Available
Half life6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by p-hydroxyclonidine.
ClearanceNot Available
ToxicityOral LD50 is 150 mg/kg in rat and 30 mg/kg in dog. Symptoms of overdose include constriction of pupils of the eye, drowsiness, high blood pressure followed by a drop in pressure, irritability, low body temperature, slowed breathing, slowed heartbeat, slowed reflexes, and weakness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Clonidine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clonidine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Clonidine.Experimental
AbirateroneThe serum concentration of Clonidine can be increased when it is combined with Abiraterone.Approved
AcebutololClonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clonidine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clonidine.Approved
AcetaminophenThe serum concentration of Clonidine can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinClonidine may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Clonidine.Investigational
AfatinibThe serum concentration of Clonidine can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clonidine.Approved, Investigational
AlbendazoleThe serum concentration of Clonidine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.Approved
AldosteroneThe serum concentration of Clonidine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Clonidine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clonidine.Vet Approved
AlfentanilThe serum concentration of Clonidine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Clonidine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Clonidine is combined with Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Clonidine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clonidine.Approved, Illicit, Investigational
AlprenololClonidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Clonidine can be increased when it is combined with Amantadine.Approved
AmbrisentanClonidine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineClonidine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Clonidine is combined with Amiloride.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Clonidine.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Clonidine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Clonidine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonidine.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Clonidine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clonidine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clonidine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Clonidine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clonidine.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Clonidine is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Clonidine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Clonidine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Clonidine is combined with Amyl Nitrite.Approved
AnvirzelClonidine may increase the atrioventricular blocking (AV block) activities of Anvirzel.Investigational
Aop200704Clonidine may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Clonidine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Clonidine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Clonidine.Approved, Investigational
ArotinololClonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Clonidine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Clonidine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Clonidine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clonidine.Approved
AstemizoleThe serum concentration of Clonidine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Clonidine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololClonidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Clonidine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Clonidine can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clonidine.Vet Approved
AzelastineClonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Clonidine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clonidine is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Clonidine can be increased when it is combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clonidine.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Clonidine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Clonidine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Barnidipine.Approved
BefunololClonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Clonidine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clonidine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Clonidine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Clonidine is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Clonidine can be increased when it is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clonidine.Approved
Benzylpenicilloyl PolylysineClonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe serum concentration of Clonidine can be increased when it is combined with Bepridil.Approved, Withdrawn
BeractantClonidine may increase the bradycardic activities of Beractant.Approved
BetaxololClonidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Clonidine.Approved
BevantololClonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BexaroteneThe serum concentration of Clonidine can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostClonidine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Clonidine can be increased when it is combined with Biperiden.Approved
BisoprololClonidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BoceprevirThe metabolism of Clonidine can be decreased when combined with Boceprevir.Approved
BopindololClonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Clonidine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Clonidine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Clonidine can be increased when it is combined with Bosutinib.Approved
BretyliumBretylium may increase the bradycardic activities of Clonidine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clonidine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Clonidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonidine.Approved, Illicit
BromocriptineBromocriptine may increase the hypertensive activities of Clonidine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clonidine.Approved, Withdrawn
BucindololClonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolClonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Clonidine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clonidine.Approved, Investigational
BupranololClonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineClonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Clonidine can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Clonidine can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clonidine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Clonidine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clonidine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Clonidine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clonidine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clonidine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Clonidine can be increased when it is combined with Cabazitaxel.Approved
CabergolineCabergoline may increase the hypertensive activities of Clonidine.Approved
CaffeineThe serum concentration of Clonidine can be increased when it is combined with Caffeine.Approved
CalfactantClonidine may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Candesartan.Approved
CandoxatrilClonidine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Captopril.Approved
CarbamazepineThe metabolism of Clonidine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Clonidine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonidine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Clonidine.Withdrawn
CarteololClonidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolClonidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Clonidine can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Clonidine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololClonidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibClonidine may increase the bradycardic activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clonidine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clonidine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clonidine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clonidine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clonidine.Approved
ChloroquineThe serum concentration of Clonidine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Clonidine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Clonidine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Clonidine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clonidine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clonidine.Approved
CholecalciferolThe metabolism of Clonidine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Clonidine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Clonidine can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Clonidine can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Clonidine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clonidine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Clonidine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Clonidine can be increased when it is combined with Citalopram.Approved
ClarithromycinThe metabolism of Clonidine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Clonidine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clonidine is combined with Clidinium.Approved
ClobazamThe metabolism of Clonidine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Clonidine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clonidine.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Clonidine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonidine is combined with Clonazepam.Approved, Illicit
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonidine.Approved, Illicit
ClotrimazoleThe metabolism of Clonidine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clonidine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Clonidine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Clonidine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clonidine.Approved, Illicit
ColchicineThe serum concentration of Clonidine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Clonidine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Clonidine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Clonidine can be decreased when combined with Crizotinib.Approved
CryptenamineClonidine may increase the hypotensive activities of Cryptenamine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Clonidine.Approved
CyclophosphamideThe serum concentration of Clonidine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Clonidine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideClonidine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clonidine.Approved
Cyproterone acetateThe serum concentration of Clonidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Clonidine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Clonidine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Clonidine can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Clonidine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonidine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Clonidine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Clonidine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Clonidine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Clonidine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinClonidine may increase the hypotensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Clonidine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Clonidine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Clonidine.Investigational
DeserpidineClonidine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clonidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Clonidine.Approved
DeslanosideClonidine may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
DesloratadineThe serum concentration of Clonidine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Clonidine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clonidine.Vet Approved
DexamethasoneThe serum concentration of Clonidine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe serum concentration of Clonidine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clonidine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clonidine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Clonidine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clonidine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Clonidine.Approved
DiclofenacThe serum concentration of Clonidine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Diclofenamide.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Clonidine is combined with Difenoxin.Approved, Illicit
DigitoxinClonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin.Approved
DigoxinClonidine may increase the atrioventricular blocking (AV block) activities of Digoxin.Approved
DihydralazineClonidine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonidine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Clonidine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clonidine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonidine.Experimental, Illicit
DiltiazemClonidine may increase the atrioventricular blocking (AV block) activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Clonidine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Clonidine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Clonidine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clonidine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Clonidine is combined with Dipyridamole.Approved
DonepezilClonidine may increase the bradycardic activities of Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clonidine.Vet Approved
DorzolamideClonidine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Clonidine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Clonidine is combined with Doxazosin.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Clonidine.Approved
DoxorubicinThe serum concentration of Clonidine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Clonidine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Clonidine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Illicit
DronedaroneThe metabolism of Clonidine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clonidine.Experimental, Illicit
DuloxetineClonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonidine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Clonidine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Clonidine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Clonidine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Clonidine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineClonidine may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Clonidine can be increased when it is combined with Elbasvir.Approved
EliglustatThe metabolism of Clonidine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Enalapril.Approved, Vet Approved
EnalaprilatClonidine may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clonidine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clonidine.Approved, Investigational
EnzalutamideThe serum concentration of Clonidine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Eplerenone.Approved
EpoprostenolClonidine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Clonidine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Clonidine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Clonidine.Approved
ErythromycinThe metabolism of Clonidine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Clonidine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Clonidine.Investigational
EsmololClonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clonidine.Approved, Illicit
EstramustineThe serum concentration of Clonidine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Clonidine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Clonidine can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clonidine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid.Approved
EthanolClonidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonidine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonidine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clonidine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clonidine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Clonidine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clonidine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clonidine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonidine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Clonidine can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clonidine.Illicit, Vet Approved
EtravirineThe serum concentration of Clonidine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Clonidine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clonidine.Approved, Illicit, Withdrawn
FenoldopamClonidine may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe serum concentration of Clonidine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Clonidine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Clonidine can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Fimasartan.Approved
FingolimodClonidine may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Clonidine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Clonidine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clonidine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clonidine.Approved, Illicit
FluoxetineThe metabolism of Clonidine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Clonidine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Clonidine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Clonidine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clonidine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Clonidine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Clonidine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clonidine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clonidine.Approved
FosphenytoinThe metabolism of Clonidine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clonidine.Approved, Illicit
FurazolidoneFurazolidone may increase the hypotensive activities of Clonidine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Clonidine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Clonidine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clonidine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Clonidine is combined with gabapentin enacarbil.Approved
GalantamineClonidine may increase the bradycardic activities of Galantamine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clonidine.Approved, Illicit
GefitinibThe serum concentration of Clonidine can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Clonidine can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Clonidine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clonidine.Approved, Illicit
GlyburideThe serum concentration of Clonidine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Clonidine can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Clonidine can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Clonidine can be increased when it is combined with Grepafloxacin.Withdrawn
GuanabenzClonidine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Clonidine.Approved
GuanethidineClonidine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Clonidine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clonidine.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Clonidine can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clonidine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Clonidine.Approved, Illicit
HexamethoniumClonidine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clonidine.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Clonidine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Clonidine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneClonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Clonidine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideClonidine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonidine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
IdelalisibThe serum concentration of Clonidine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Clonidine.Approved, Investigational
ImatinibThe metabolism of Clonidine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Clonidine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Clonidine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Indapamide.Approved
IndenololClonidine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Clonidine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Clonidine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminClonidine may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Clonidine.Approved
IproclozideIproclozide may increase the hypotensive activities of Clonidine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Clonidine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Clonidine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Clonidine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clonidine.Approved, Vet Approved
IsoniazidThe metabolism of Clonidine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Clonidine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clonidine.Approved
ItraconazoleThe metabolism of Clonidine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineClonidine may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Clonidine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Clonidine can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Clonidine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinClonidine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clonidine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clonidine.Approved
KetoconazoleThe metabolism of Clonidine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolClonidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineClonidine may increase the hypotensive activities of Lacidipine.Approved
LacosamideClonidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonidine.Approved, Investigational
LanreotideClonidine may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Clonidine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Clonidine can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostClonidine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Clonidine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Clonidine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Clonidine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clonidine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levocetirizine.Approved
LevodopaClonidine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Clonidine can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clonidine.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Clonidine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clonidine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Clonidine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Clonidine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Clonidine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Clonidine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Clonidine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Clonidine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Clonidine.Illicit
LofexidineClonidine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Clonidine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Clonidine can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Clonidine can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Clonidine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clonidine.Approved
LorcaserinThe metabolism of Clonidine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Losartan.Approved
LovastatinThe metabolism of Clonidine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clonidine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Clonidine.Investigational
LucinactantClonidine may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Clonidine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Clonidine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Clonidine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine.Approved
MacitentanClonidine may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Vet Approved
ManidipineClonidine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Clonidine is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Clonidine can be increased when it is combined with Maprotiline.Approved
MebanazineMebanazine may increase the hypotensive activities of Clonidine.Withdrawn
MebendazoleThe serum concentration of Clonidine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clonidine.Vet Approved
MefloquineThe serum concentration of Clonidine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Clonidine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clonidine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clonidine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonidine.Approved, Vet Approved
MeprobamateThe serum concentration of Clonidine can be increased when it is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonidine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Clonidine is combined with Metaxalone.Approved
MethadoneThe serum concentration of Clonidine can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Clonidine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clonidine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clonidine.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonidine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clonidine.Approved
MethotrimeprazineClonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clonidine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Clonidine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clonidine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Clonidine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Clonidine.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clonidine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Clonidine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Clonidine.Approved
MetoprololClonidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineClonidine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Clonidine can be decreased when combined with Mexiletine.Approved
MianserinThe therapeutic efficacy of Clonidine can be decreased when used in combination with Mianserin.Approved
MibefradilThe serum concentration of Clonidine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Clonidine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Clonidine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Clonidine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Clonidine.Approved
MinaprineMinaprine may increase the hypotensive activities of Clonidine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clonidine.Approved
MirabegronThe metabolism of Clonidine can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Clonidine.Approved
MitomycinThe serum concentration of Clonidine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Clonidine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Clonidine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Clonidine.Approved
ModafinilThe serum concentration of Clonidine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clonidine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Clonidine.Approved
MorphineThe serum concentration of Clonidine can be increased when it is combined with Morphine.Approved, Investigational
MoxonidineClonidine may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Investigational
NadololClonidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafcillinThe serum concentration of Clonidine can be decreased when it is combined with Nafcillin.Approved
NaftopidilClonidine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clonidine.Approved
NaltrexoneThe serum concentration of Clonidine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Clonidine can be increased when it is combined with Naringenin.Experimental
NebivololThe risk or severity of adverse effects can be increased when Clonidine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Clonidine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Clonidine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Clonidine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Clonidine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Clonidine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Clonidine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Clonidine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Clonidine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nifedipine.Approved
NiguldipineClonidine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Clonidine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineClonidine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clonidine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clonidine.Approved
NitrazepamThe serum concentration of Clonidine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Clonidine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Clonidine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Clonidine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Clonidine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clonidine.Approved, Vet Approved
NorethisteroneThe serum concentration of Clonidine can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Clonidine.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Clonidine.Approved
ObinutuzumabClonidine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Clonidine.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Clonidine.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonidine.Approved, Investigational
OlaparibThe metabolism of Clonidine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clonidine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Clonidine is combined with Olopatadine.Approved
OmapatrilatClonidine may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe serum concentration of Clonidine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clonidine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Clonidine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Clonidine.Approved, Illicit
OrphenadrineClonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clonidine.Investigational
OsimertinibThe serum concentration of Clonidine can be increased when it is combined with Osimertinib.Approved
OuabainClonidine may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clonidine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Clonidine is combined with Oxetacaine.Investigational
OxprenololClonidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clonidine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonidine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clonidine.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Clonidine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Clonidine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Clonidine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonidine.Approved
Palmitic AcidThe serum concentration of Clonidine can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Clonidine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Clonidine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Clonidine is combined with Papaverine.Approved
ParaldehydeClonidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the hypotensive activities of Clonidine.Approved
ParoxetineThe metabolism of Clonidine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideClonidine may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Clonidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololClonidine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonidine.Approved, Vet Approved
PentobarbitalThe metabolism of Clonidine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumClonidine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Clonidine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
PerazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clonidine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clonidine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clonidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Clonidine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Clonidine.Withdrawn
PhenobarbitalThe metabolism of Clonidine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineClonidine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Clonidine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Clonidine.Withdrawn
PhentolamineClonidine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe metabolism of Clonidine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Clonidine can be increased when it is combined with Pimozide.Approved
PinacidilClonidine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololClonidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clonidine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Clonidine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Clonidine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Clonidine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Clonidine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Clonidine can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideClonidine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Clonidine is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Clonidine can be increased when it is combined with Ponatinib.Approved
Poractant alfaClonidine may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Clonidine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololClonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleClonidine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clonidine.Approved
PravastatinThe serum concentration of Clonidine can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clonidine.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Clonidine.Approved
PrednisoneThe serum concentration of Clonidine can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clonidine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Clonidine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Clonidine.Approved
PrimidoneThe metabolism of Clonidine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Clonidine can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clonidine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonidine.Approved, Vet Approved
ProgesteroneThe serum concentration of Clonidine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Clonidine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Clonidine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Clonidine can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clonidine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clonidine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Clonidine.Approved
PropranololClonidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Clonidine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Clonidine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clonidine.Approved, Illicit
QuercetinThe serum concentration of Clonidine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Clonidine can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Clonidine can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Clonidine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Clonidine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Clonidine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Clonidine.Approved
RanitidineThe serum concentration of Clonidine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Clonidine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Clonidine.Approved
ReboxetineThe serum concentration of Clonidine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Clonidine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonidine.Approved
RemikirenRemikiren may increase the hypotensive activities of Clonidine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonidine.Approved, Withdrawn
RescinnamineClonidine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clonidine.Approved
RifabutinThe metabolism of Clonidine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Clonidine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Clonidine can be increased when combined with Rifapentine.Approved
RilmenidineClonidine may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Clonidine can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Clonidine is combined with Riociguat.Approved
RisperidoneClonidine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Clonidine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Clonidine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabClonidine may increase the hypotensive activities of Rituximab.Approved
RivastigmineClonidine may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RolapitantThe serum concentration of Clonidine can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clonidine.Vet Approved
RopiniroleClonidine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonidine.Approved
RotigotineClonidine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clonidine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Clonidine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clonidine.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Clonidine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Clonidine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Clonidine is combined with Sage 547.Investigational
SaprisartanClonidine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Clonidine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Clonidine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clonidine.Approved, Vet Approved
SelegilineThe serum concentration of Clonidine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagClonidine may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clonidine.Approved, Withdrawn
SertralineThe serum concentration of Clonidine can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clonidine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Clonidine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Clonidine.Approved
SiltuximabThe serum concentration of Clonidine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Clonidine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Clonidine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Clonidine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitaxentanClonidine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Clonidine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
SorafenibThe serum concentration of Clonidine can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolClonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilClonidine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Clonidine.Approved
St. John's WortThe serum concentration of Clonidine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Clonidine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Clonidine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Clonidine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Clonidine can be decreased when it is combined with Streptozocin.Approved
SufentanilClonidine may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Clonidine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Clonidine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonidine.Approved
SumatriptanThe serum concentration of Clonidine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Clonidine can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantClonidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Clonidine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Clonidine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Clonidine.Approved, Investigational
TamoxifenThe serum concentration of Clonidine can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Clonidine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Clonidine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clonidine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Clonidine can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe metabolism of Clonidine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Clonidine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clonidine.Approved
TemocaprilClonidine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Clonidine can be increased when it is combined with Temsirolimus.Approved
TenofovirThe metabolism of Clonidine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Clonidine is combined with Terazosin.Approved
TerbinafineThe metabolism of Clonidine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Clonidine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Clonidine can be decreased when it is combined with Teriflunomide.Approved
TerlipressinClonidine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Clonidine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Clonidine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clonidine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clonidine.Investigational
ThalidomideClonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Clonidine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clonidine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clonidine.Approved, Vet Approved
ThioridazineThe metabolism of Clonidine can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonidine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Clonidine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Clonidine is combined with Tiapride.Investigational
TiboloneClonidine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Clonidine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Clonidine can be decreased when combined with Ticlopidine.Approved
TicrynafenClonidine may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clonidine.Vet Approved
TimololClonidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TipranavirThe metabolism of Clonidine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Clonidine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Clonidine.Approved, Investigational
TolazolineClonidine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonidine.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypotensive activities of Clonidine.Approved
TolvaptanThe serum concentration of Clonidine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clonidine.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Clonidine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonidine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clonidine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clonidine.Experimental
TranylcypromineThe metabolism of Clonidine can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Clonidine.Approved
TrazodoneThe serum concentration of Clonidine can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Clonidine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Clonidine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Clonidine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clonidine.Approved
TrichlormethiazideClonidine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Clonidine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Clonidine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinClonidine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanClonidine may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe serum concentration of Clonidine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Clonidine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clonidine.Approved
TroleandomycinThe serum concentration of Clonidine can be increased when it is combined with Troleandomycin.Approved
Uc1010The risk or severity of adverse effects can be increased when Clonidine is combined with Uc1010.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Clonidine.Approved, Investigational
UnoprostoneClonidine may increase the hypotensive activities of Unoprostone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clonidine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Clonidine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Clonidine.Approved
VemurafenibThe serum concentration of Clonidine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Clonidine.Approved
VerapamilClonidine may increase the atrioventricular blocking (AV block) activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Clonidine is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Clonidine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Clonidine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Clonidine can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineClonidine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Clonidine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clonidine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clonidine.Vet Approved
XylometazolineClonidine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Clonidine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clonidine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Clonidine is combined with Ziconotide.Approved
ZimelidineThe serum concentration of Clonidine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Clonidine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clonidine.Vet Approved
ZolpidemClonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clonidine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clonidine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonidine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.
References
Synthesis Reference

David R. Pierce, William D. Dean, Michael E. Deason, “Process for preparation of clonidine derivatives.” U.S. Patent US5684156, issued October, 1968.

US5684156
General References
  1. Schapiro NA: "Dude, you don't have Tourette's:" Tourette's syndrome, beyond the tics. Pediatr Nurs. 2002 May-Jun;28(3):243-6, 249-53. [PubMed:12087644 ]
  2. Hossmann V, Maling TJ, Hamilton CA, Reid JL, Dollery CT: Sedative and cardiovascular effects of clonidine and nitrazepam. Clin Pharmacol Ther. 1980 Aug;28(2):167-76. [PubMed:7398184 ]
External Links
ATC CodesS01EA04N02CX02C02LC01C02AC01C02LC51
AHFS Codes
  • 24:08.16
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9632
Blood Brain Barrier+0.9402
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6305
P-glycoprotein inhibitor INon-inhibitor0.9061
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.745
CYP450 2C9 substrateNon-substrate0.8219
CYP450 2D6 substrateNon-substrate0.6984
CYP450 3A4 substrateNon-substrate0.6353
CYP450 1A2 substrateNon-inhibitor0.8998
CYP450 2C9 inhibitorNon-inhibitor0.7681
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.8732
CYP450 3A4 inhibitorNon-inhibitor0.8332
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.803
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9303
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity3.5030 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7232
hERG inhibition (predictor II)Non-inhibitor0.8905
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim
  • Aveva drug delivery systems inc
  • Mylan technologies inc
  • Tris pharma inc
  • Pharmaforce inc
  • Bioniche pharma usa llc
  • Actavis elizabeth llc
  • American therapeutics inc
  • Dava pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Impax laboratories inc
  • Interpharm inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Unichem laboratories ltd
  • Vintage pharmaceuticals llc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Shionogi pharma inc
Packagers
Dosage forms
FormRouteStrength
TabletOral0.025 mg
TabletOral.1 mg
TabletOral.2 mg
Patch, extended releaseTransdermal.1 mg/24h
Patch, extended releaseTransdermal.2 mg/24h
Patch, extended releaseTransdermal.3 mg/24h
Injection, solutionEpidural100 ug/mL
Injection, solutionEpidural500 ug/mL
PatchTransdermal.1 mg/d
PatchTransdermal.2 mg/d
PatchTransdermal.3 mg/d
Injection, solutionIntravenous100 ug/mL
Injection, solutionIntravenous500 ug/mL
TabletOral.1 mg/1
TabletOral.2 mg/1
TabletOral.3 mg/1
Tablet, extended releaseOral.1 mg/1
Tablet, extended releaseOral.2 mg/1
TabletOral
Injection, solutionEpidural.1 mg/mL
Injection, solutionEpidural.5 mg/mL
Tablet, extended releaseOral.17 mg/1
For suspension, extended releaseOral.09 mg/mL
Tablet, extended releaseOral.26 mg/1
TabletOral0.1 mg
TabletOral0.2 mg
Prices
Unit descriptionCostUnit
Catapres-TTS-3 4 0.3 mg/24hr Patches Box328.42USD box
CloNIDine HCl 4 0.3 mg/24hr Patches Box279.9USD box
Catapres-TTS-2 4 0.2 mg/24hr Patches Box236.75USD box
CloNIDine HCl 4 0.2 mg/24hr Patches Box201.75USD box
Catapres-TTS-1 4 0.1 mg/24hr Patches Box141.08USD box
CloNIDine HCl 4 0.1 mg/24hr Patches Box119.84USD box
Catapres-tts 3 patch78.95USD patch
Clonidine 0.3 mg/day patch67.28USD patch
Clonidine hcl powder53.09USD g
Clonidine 0.2 mg/day patch48.5USD patch
Duraclon 500 mcg/ml vial47.4USD ml
Catapres-tts 2 patch39.23USD patch
Clonidine 0.1 mg/day patch28.81USD patch
Catapres-tts 1 patch21.18USD patch
Clonidine 5000 mcg/10 ml vial21.0USD ml
Duraclon 0.1 mg/ml vial14.4USD ml
Clonidine 1000 mcg/10 ml vial5.04USD ml
Catapres 0.3 mg tablet2.98USD tablet
Catapres 0.2 mg tablet2.35USD tablet
Catapres 0.1 mg tablet1.57USD tablet
Clonidine hcl 0.3 mg tablet0.5USD tablet
Clonidine hcl 0.2 mg tablet0.35USD tablet
Catapres 0.2 mg Tablet0.35USD tablet
Apo-Clonidine 0.2 mg Tablet0.33USD tablet
Novo-Clonidine 0.2 mg Tablet0.33USD tablet
Nu-Clonidine 0.2 mg Tablet0.33USD tablet
Dixarit 0.025 mg Tablet0.28USD tablet
Clonidine hcl 0.1 mg tablet0.24USD tablet
Catapres 0.1 mg Tablet0.19USD tablet
Apo-Clonidine 0.1 mg Tablet0.18USD tablet
Novo-Clonidine 0.1 mg Tablet0.18USD tablet
Nu-Clonidine 0.1 mg Tablet0.18USD tablet
Apo-Clonidine 0.025 mg Tablet0.16USD tablet
Novo-Clonidine 0.025 mg Tablet0.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5869100 No1993-10-132013-10-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point3053,202,660
water solubilityAppreciableNot Available
logP1.59HANSCH,C & LEO,AJ (1985)
Caco2 permeability-4.59ADME Research, USCD
pKa8.05 (at 25 °C)KONTTURI,K & MURTOMAKI,L (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.48 mg/mLALOGPS
logP2.55ALOGPS
logP2.49ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area36.42 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity59.09 m3·mol-1ChemAxon
Polarizability21.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-003r-5970000000-33c27878b8b7ad9d5d75View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassHalobenzenes
Direct ParentDichlorobenzenes
Alternative Parents
Substituents
  • 1,3-dichlorobenzene
  • Aryl halide
  • Aryl chloride
  • 2-imidazoline
  • Guanidine
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL: alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 2002 Jan;300(1):282-90. [PubMed:11752127 ]
  2. Lavand'homme PM, Ma W, De Kock M, Eisenach JC: Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology. 2002 Oct;97(4):972-80. [PubMed:12357167 ]
  3. Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M: The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol. 2004 Aug 23;497(2):161-71. [PubMed:15306201 ]
  4. Ozdogan UK, Lahdesmaki J, Mansikka H, Scheinin M: Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur J Pharmacol. 2004 Feb 6;485(1-3):193-6. [PubMed:14757140 ]
  5. Wang XM, Zhang ZJ, Bains R, Mokha SS: Effect of antisense knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain. 2002 Jul;98(1-2):27-35. [PubMed:12098614 ]
  6. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. PDSP Ki Database [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755 ]
  2. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  3. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
  4. Martel F, Vetter T, Russ H, Grundemann D, Azevedo I, Koepsell H, Schomig E: Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):320-6. [PubMed:8878062 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924 ]
  2. Martel F, Grundemann D, Calhau C, Schomig E: Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters. Naunyn Schmiedebergs Arch Pharmacol. 2001 Jan;363(1):40-9. [PubMed:11191835 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
  2. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23